Drugs / HER2 FPBMC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07441889 | Jun 2026 → Oct 2029 expected | breast cancer, prostate cancer | University of Virginia | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2 FPBMC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07441889 ↗ |
| Modality | Cell therapy | “armed fresh peripheral blood mononuclear cells (HER2 FPBMC)” NCT07441889 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT07441889 ↗ |